Author:
Popovic Jadranka,Geffner Mitchell E.,Rogol Alan D.,Silverman Lawrence A.,Kaplowitz Paul B.,Mauras Nelly,Zeitler Philip,Eugster Erica A.,Klein Karen O.
Abstract
Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatment selection. Five GnRHa's are currently FDA-approved and prescribed in the US and published data suggest similar safety and efficacy profiles over the first year of treatment. One- and 3-month intramuscular (IM) leuprolide acetate (LA) have long-term safety and efficacy data and allow for flexible dosing. Six-month IM triptorelin pamoate offers a longer duration of treatment, but without long-term efficacy and outcome data. Six-month subcutaneous (SQ) LA combines a SQ route of injection and long duration of action but lacks long-term efficacy and outcome data. The 12-month SQ histrelin acetate implant avoids injections and offers the longest duration of action, but requires a minor surgical procedure with local or general anesthesia. Factors in treatment selection include route of administration, needle size, injection volume, duration of action, and cost. The current GnRHa landscape provides options with varying benefits and risks, allowing physicians and caregivers to select the most appropriate therapy based on the specific needs and concerns of the child and the caregiver. Agents have different advantages and disadvantages for use, with no one agent displaying superiority.
Subject
Pediatrics, Perinatology and Child Health
Reference90 articles.
1. National Institute of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development,2016
2. Treatment and outcomes of precocious puberty: an update;Fuqua;J Clin Endocrinol Metab.,2013
3. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or Gnrh analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method;Kauli;Horm Res.,1997
4. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function;Pasquino;J Clin Endocrinol Metab.,2008
5. Randomised trial of Lhrh analogue treatment on final height in girls with onset of puberty aged 75-85 years;Cassio;Arch Dis Child.,1999
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献